Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis (NCT06947993)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
🩺 Plain-English Summary (8th-Grade Level)
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Who can join: Review the eligibility criteria below.
Location: Novartis Investigative Site — Birmingham, Alabama
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (105 Sites)
Showing the first 25 of 105 sites.
- Novartis Investigative Site — Birmingham, Alabama
- Novartis Investigative Site — Birmingham, Alabama
- Novartis Investigative Site — Fort Smith, Arkansas
- Novartis Investigative Site — Fountain Valley, California
- Novartis Investigative Site — Los Angeles, California
- Novartis Investigative Site — Sacramento, California
- Novartis Investigative Site — Santa Ana, California
- Novartis Investigative Site — Santa Monica, California
- Novartis Investigative Site — Washington D.C., District of Columbia
- Novartis Investigative Site — Miami, Florida
- Novartis Investigative Site — St. Petersburg, Florida
- Novartis Investigative Site — Atlanta, Georgia
- Novartis Investigative Site — Macon, Georgia
- Novartis Investigative Site — Louisville, Kentucky
- Novartis Investigative Site — Brighton, Massachusetts
- Novartis Investigative Site — Troy, Michigan
- Novartis Investigative Site — Saint Joseph, Missouri
- Novartis Investigative Site — Portsmouth, New Hampshire
- Novartis Investigative Site — Brooklyn, New York
- Novartis Investigative Site — Arlington, Texas
- Novartis Investigative Site — Cypress, Texas
- Novartis Investigative Site — Dallas, Texas
- Novartis Investigative Site — Houston, Texas
- Novartis Investigative Site — San Antonio, Texas
- Novartis Investigative Site — Caba, Buenos Aires
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.